These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 22351746)

  • 21. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
    Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rheum palmatum extract exerts anti-hepatocellular carcinoma effects by inhibiting signal transducer and activator of transcription 3 signaling.
    Tan ZB; Fan HJ; Wu YT; Xie LP; Bi YM; Xu HL; Chen HM; Li J; Liu B; Zhou YC
    J Ethnopharmacol; 2019 Mar; 232():62-72. PubMed ID: 30553869
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
    Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS
    Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
    Tong M; Che N; Zhou L; Luk ST; Kau PW; Chai S; Ngan ES; Lo CM; Man K; Ding J; Lee TK; Ma S
    J Hepatol; 2018 Oct; 69(4):826-839. PubMed ID: 29885413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts.
    Jia WD; Xu GL; Xu RN; Sun HC; Wang L; Yu JH; Wang J; Li JS; Zhai ZM; Xue Q
    J Cancer Res Clin Oncol; 2003 Jun; 129(6):327-34. PubMed ID: 12811549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody.
    Chen KF; Chen HL; Shiau CW; Liu CY; Chu PY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
    Br J Pharmacol; 2013 Feb; 168(3):658-72. PubMed ID: 22978563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma.
    Huynh H; Chow PK; Palanisamy N; Salto-Tellez M; Goh BC; Lee CK; Somani A; Lee HS; Kalpana R; Yu K; Tan PH; Wu J; Soong R; Lee MH; Hor H; Soo KC; Toh HC; Tan P
    J Hepatol; 2008 Jul; 49(1):52-60. PubMed ID: 18490075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic effects of the PKR inhibitor C16 suppressing tumor proliferation and angiogenesis in hepatocellular carcinoma in vitro and in vivo.
    Watanabe T; Ninomiya H; Saitou T; Takanezawa S; Yamamoto S; Imai Y; Yoshida O; Kawakami R; Hirooka M; Abe M; Imamura T; Hiasa Y
    Sci Rep; 2020 Mar; 10(1):5133. PubMed ID: 32198380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic Inhibitory Effect of Traditional Chinese Medicine Astragaloside IV and Curcumin on Tumor Growth and Angiogenesis in an Orthotopic Nude-Mouse Model of Human Hepatocellular Carcinoma.
    Zhang S; Tang D; Zang W; Yin G; Dai J; Sun YU; Yang Z; Hoffman RM; Guo X
    Anticancer Res; 2017 Feb; 37(2):465-473. PubMed ID: 28179291
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The epigallocatechin gallate derivative Y
    Liao ZH; Zhu HQ; Chen YY; Chen RL; Fu LX; Li L; Zhou H; Zhou JL; Liang G
    J Ethnopharmacol; 2020 Sep; 259():112852. PubMed ID: 32278759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blocking FGF2 with a new specific monoclonal antibody impairs angiogenesis and experimental metastatic melanoma, suggesting a potential role in adjuvant settings.
    de Aguiar RB; Parise CB; Souza CR; Braggion C; Quintilio W; Moro AM; Navarro Marques FL; Buchpiguel CA; Chammas R; de Moraes JZ
    Cancer Lett; 2016 Feb; 371(2):151-60. PubMed ID: 26655277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Antitumor and anti-angiogenic effects of manumycin on human hepatocellular carcinoma HepG2 xenografts in nude mice].
    Zhou JM; Zhu XF; Liu ZC; Fu LW; Yang XP; Liang YJ; Pan QC
    Ai Zheng; 2005 Aug; 24(8):935-9. PubMed ID: 16086869
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interferon-α/β and anti-fibroblast growth factor receptor 1 monoclonal antibody suppress hepatic cancer cells in vitro and in vivo.
    Sasaki S; Ishida T; Toyota M; Ota A; Suzuki H; Takaoka A; Yasui H; Yamamoto H; Takagi H; Maeda M; Seito T; Tsujisaki M; Shinomura Y; Imai K
    PLoS One; 2011 May; 6(5):e19618. PubMed ID: 21573021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling.
    Shigesawa T; Maehara O; Suda G; Natsuizaka M; Kimura M; Shimazaki T; Yamamoto K; Yamada R; Kitagataya T; Nakamura A; Suzuki K; Ohara M; Kawagishi N; Umemura M; Nakai M; Sho T; Morikawa K; Ogawa K; Ohnishi S; Sugiyama M; Mizokami M; Takeda H; Sakamoto N
    Carcinogenesis; 2021 Feb; 42(1):58-69. PubMed ID: 32449510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
    Bagi CM; Gebhard DF; Andresen CJ
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma.
    Tovar V; Cornella H; Moeini A; Vidal S; Hoshida Y; Sia D; Peix J; Cabellos L; Alsinet C; Torrecilla S; Martinez-Quetglas I; Lozano JJ; Desbois-Mouthon C; Solé M; Domingo-Domenech J; Villanueva A; Llovet JM
    Gut; 2017 Mar; 66(3):530-540. PubMed ID: 26658144
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of hepatocellular carcinoma cell growth by an anti-insulin-like growth factor-I receptor monoclonal antibody.
    Yue L; Wang Y; Wang H; Gao H; Liang J; Sui A; Xiang J; Zhou F; Xu C; Zhao W; Liang W; Yao R
    Oncol Rep; 2012 Oct; 28(4):1453-60. PubMed ID: 22895605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effective inhibition of xenografts of hepatocellular carcinoma (HepG2) by rapamycin and bevacizumab in an intrahepatic model.
    Ong LC; Song IC; Jin Y; Kee IH; Siew E; Yu S; Thng CH; Huynh H; Chow PK
    Mol Imaging Biol; 2009; 11(5):334-42. PubMed ID: 19330383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The kynurenine derivative 3-HAA sensitizes hepatocellular carcinoma to sorafenib by upregulating phosphatases.
    Gan G; Shi Z; Shangguan C; Zhang J; Yuan Y; Chen L; Liu W; Li B; Meng S; Xiong W; Mi J
    Theranostics; 2021; 11(12):6006-6018. PubMed ID: 33897895
    [No Abstract]   [Full Text] [Related]  

  • 40. TQ inhibits hepatocellular carcinoma growth in vitro and in vivo via repression of Notch signaling.
    Ke X; Zhao Y; Lu X; Wang Z; Liu Y; Ren M; Lu G; Zhang D; Sun Z; Xu Z; Song JH; Cheng Y; Meltzer SJ; He S
    Oncotarget; 2015 Oct; 6(32):32610-21. PubMed ID: 26416455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.